SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-046056
Filing Date
2023-12-26
Accepted
2023-12-26 08:05:34
Documents
13
Period of Report
2023-12-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50230
2 ex99-1.htm EX-99.1 21156
  Complete submission text file 0001493152-23-046056.txt   255144

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dare-20231221.xsd EX-101.SCH 3033
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dare-20231221_lab.xml EX-101.LAB 34240
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dare-20231221_pre.xml EX-101.PRE 22371
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3309
Mailing Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122
Business Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122 858-926-7655
Dare Bioscience, Inc. (Filer) CIK: 0001401914 (see all company filings)

IRS No.: 204139823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36395 | Film No.: 231511389
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)